Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 30, 2002

Study Completion Date

May 31, 2007

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

TLK199 HCl Liposomes for Injection

Trial Locations (9)

35294

University of Alabama at Birmingham, Birmingham

37203

The Sarah Cannon Cancer Center, Nashville

60077

Midwest Cancer Research Group, Skokie

60637

University of Chicago, Chicago

75231

Texas Cancer Associates, Dallas

77030

M.D. Anderson Cancer Center, Houston

78229

University of Texas Health Science Center at San Antonio, San Antonio

90404

The Angeles Clinic & Research Institute, Los Angeles

97239

Oregon Health & Science University, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Telik

INDUSTRY